Alto Neuroscience (NYSE:ANRO) Trading 7.3% Higher – Time to Buy?

Alto Neuroscience, Inc. (NYSE:ANRO) shares traded up 7.3% on Wednesday . The stock traded as high as $22.09 and last traded at $22.4140. 13,949 shares were traded during mid-day trading, a decline of 93% from the average session volume of 202,469 shares. The stock had previously closed at $20.88.

Wall Street Analysts Forecast Growth

ANRO has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Robert W. Baird upped their price objective on Alto Neuroscience from $16.00 to $22.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Chardan Capital increased their price objective on Alto Neuroscience from $15.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, January 5th. BTIG Research boosted their target price on Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Finally, Wall Street Zen upgraded Alto Neuroscience from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Alto Neuroscience currently has an average rating of “Moderate Buy” and a consensus price target of $26.50.

Alto Neuroscience Price Performance

The firm has a market capitalization of $701.25 million, a price-to-earnings ratio of -9.86 and a beta of 2.52. The company has a quick ratio of 15.42, a current ratio of 15.42 and a debt-to-equity ratio of 0.20. The company’s fifty day moving average is $17.50 and its two-hundred day moving average is $12.68.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Vanguard Personalized Indexing Management LLC raised its position in shares of Alto Neuroscience by 13.7% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock valued at $69,000 after acquiring an additional 2,055 shares during the period. Peapod Lane Capital LLC grew its stake in Alto Neuroscience by 1.1% in the third quarter. Peapod Lane Capital LLC now owns 281,963 shares of the company’s stock valued at $1,136,000 after acquiring an additional 3,106 shares during the period. Torren Management LLC bought a new stake in shares of Alto Neuroscience in the fourth quarter worth about $62,000. XTX Topco Ltd grew its position in shares of Alto Neuroscience by 32.2% in the 4th quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock valued at $371,000 after purchasing an additional 5,078 shares during the period. Finally, Citizens Financial Group Inc. RI grew its position in shares of Alto Neuroscience by 19.0% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company’s stock valued at $161,000 after purchasing an additional 6,394 shares during the period.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.